Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 1Phase 1/2 1

Status

Completed 5

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5Thoracic 1Gynecologic 1Genitourinary 1CNS 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 42Breast Neoplasms 28Parkinson Disease 4, Autosomal Dominant Lewy Body 23Neoplasms 22Multiple Myeloma 18Leukemia, Myeloid, Acute 14Neoplasm Metastasis 11Carcinoma, Renal Cell 10Leukemia 10Melanoma 10Ovarian Neoplasms 10Recurrence 10Leukemia, Lymphocytic, Chronic, B-Cell 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Adenocarcinoma 8Carcinoma, Hepatocellular 8Colorectal Neoplasms 8Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Lung Neoplasms 8Myelodysplastic Syndromes 8Prostatic Neoplasms 8Stomach Neoplasms 8Lymphoma, Follicular 7Bronchiolitis Obliterans Syndrome 6Carcinoma 6Lymphoma 6Lymphoma, Non-Hodgkin 6Small Cell Lung Carcinoma 6Urinary Bladder Neoplasms 6Cholangiocarcinoma 5

Interventions

pembrolizumab 3Paclitaxel 2Docetaxel 2sacituzumab govitecan 1Nivolumab 1Irinotecan 1Fluorouracil 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Has results × Has announcements × Esophageal Neoplasms × Clear all
NCT03189719 2024-10-15

KEYNOTE-590

Merck Sharp & Dohme LLC

Phase 3 Completed
749 enrolled 40 charts 1 FDA
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT02564263 2023-03-13

KEYNOTE-181

Merck Sharp & Dohme LLC

Phase 3 Completed
628 enrolled 27 charts 1 FDA
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT02559687 2022-09-14

KEYNOTE-180

Merck Sharp & Dohme LLC

Phase 2 Completed
121 enrolled 14 charts 1 FDA
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT02569242 2022-07-06

Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer

Ono Pharmaceutical Co., Ltd.

Phase 3 Completed
419 enrolled 20 charts 1 FDA
Gastrointestinal

Esophageal Neoplasms

NCT01631552 2021-08-12

Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer

Gilead Sciences

Phase 1/2 Completed
515 enrolled 28 charts 1 FDA
BreastCNSGastrointestinalGenitourinaryGynecologicThoracic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡